n-Lorem Foundation Applauds FDA’s Important and Highly Constructive Guidance for Individualized ASO Treatments for Patients with Ultra-Rare Conditions
The guidance is specific, clear and consistent with proposals made by n-Lorem, and will greatly facilitate rapid and efficient treatment of these needy patients.\nDr.
- The guidance is specific, clear and consistent with proposals made by n-Lorem, and will greatly facilitate rapid and efficient treatment of these needy patients.\nDr.
- Crooke added, \xe2\x80\x9cWe believe that only when all stakeholders, including the FDA, work together collaboratively, can we maximize the number of patients that will benefit from experimental ASO treatment.
- The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific.
- To learn more about the n-Lorem Foundation, visit www.nlorem.org , and follow us on Twitter , Facebook , LinkedIn and YouTube .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210503005123/en/\n'